A Nature Communications study found Vascudyne’s externally supported bioengineered vessel remained patent for up to 550 days in sheep, including a year without anticoagulation.
NICE has supported routine NHS access to ex-situ liver machine perfusion, potentially reducing funding variation for technology designed to assess and preserve donor organs before transplantation.
The 85-patient BCI-REHAB study found a 4.5-point treatment difference favoring IpsiHand and a number needed to treat of 2.2, although substantial control-group withdrawal complicates interpretation.
FDA cleared Wellvii BP Go as a Class II non-invasive blood pressure system after published validation found its finger-based measurements met ISO 81060-2:2018 requirements.
St. Joseph’s Health is integrating Coreline Soft’s AVIEW into its existing INFINITT PACS, allowing AI pre-analysis of lung screening CTs without sending radiologists into a separate application.
MONARCH QUEST 3 adds AI nodule segmentation, improved registration, 3D orientation and broader cone-beam CT integration as Johnson & Johnson targets more reliable lung nodule navigation.
FDA’s PMA supplement expands RHA Redensity Eye into infraorbital volume correction, backed by a 233-patient safety population and mandatory device-specific injector training.
The all-stock transaction values Ambros Therapeutics at $500 million and pairs its pivotal neridronate programme with a $150 million financing designed to fund development through Phase 3 data and an FDA filing.
Cortechs.ai’s NeuroQuant PET can automatically quantify amyloid PET uptake, generate SUVR and Centiloid measurements and send structured results into imaging workflows.
Aqua Medical has treated the second US patient in RESTORE-1, a 20-person IDE study evaluating whether RF vapor ablation of proximal intestinal mucosa can improve HbA1c.